Autoimmune & Rheumatology Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

This Phase 3 trial compares two biologic treatments, guselkumab and golimumab, in adults with psoriatic arthritis who have not had good results with prior TNF inhibitors. The study is testing whether switching to guselkumab, which targets a different part of the immune system, is more effective than switching to another TNF inhibitor. Results from this research could help patients find better options for managing psoriatic arthritis symptoms when initial treatments are not enough.

A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

This Phase 3 study is investigating berobenatide, a medication taken once a week, in adults with knee osteoarthritis who are overweight or have obesity, including those with type 2 diabetes. If successful, this treatment might reduce knee pain and improve movement while also addressing weight issues, which could enhance overall quality of life. The trial is recruiting in the United States and will continue for about a year.

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

This Phase 3 trial is testing the safety of apremilast, an oral medicine, in children with oral ulcers caused by Behçet's disease or juvenile psoriatic arthritis. The goal is to find a new long-term treatment option that is easier for children to manage compared to current therapies. The study is recruiting children aged 2 years and older in several countries, offering hope for better symptom control in young patients.

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

This Phase 2 study tested nipocalimab, an antibody treatment, in adults with primary Sjogren's syndrome, a condition that causes dry eyes and mouth. The trial has completed and results are available, providing valuable information on whether this new treatment can improve symptoms more effectively than existing options. The study was conducted internationally, aiming to expand treatment choices for people with this autoimmune disease.

Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study

This study explores whole-body cryotherapy, a treatment involving exposure to very cold temperatures, as a potential way to reduce symptoms in people with chronic fatigue conditions such as ME/CFS, fibromyalgia, and Long COVID. The research aims to see if this non-drug approach can help ease fatigue, brain fog, and pain by improving inflammation and nervous system function. The trial is recruiting in the United Kingdom with a small group of participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.